BioLine RX Stock

BioLine RX Gross Profit

Delisted

The Gross Profit of BioLine RX (BLRX.TA) as of Jul 16, 2026 is 19.68 M USD. In the previous year, Gross Profit was 1.11 M USD — a change of 1,675.90% (higher).

Gross Profit

19.68 MUSD

YoY

1,675.90%

Last updated:

Gross Profit of BioLine RX is 2026 19.68 M USD. Gross Profit of BioLine RX was 2025 1.11 M USD. It decreases by 1,675.90% higher compared to the previous year.

The BioLine RX Gross Profit history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

GROSS MARGIN (%)
Date
GROSS MARGIN (%)
Jan 1, 2017
0.00 base
Jan 1, 2018
0.00 base
Jan 1, 2019
0.00 base
Jan 1, 2020
0.00 base
Jan 1, 2021
0.00 base
Jan 1, 2022
0.00 base
Jan 1, 2023
23.08 base
Jan 1, 2024
67.99 base
YEARGROSS MARGIN (%)
2024 67.99
2023 23.08
2022 -
2021 -
2020 -
2019 -
2018 -
2017 -
2016 -
2015 -
2014 -
2013 -
2012 -
2011 -
2010 77.38
2009 64.60
2008 -
2007 -
2006 -
2005 -
Access this data via the Eulerpool API
Get Free API Key

BioLine RX Revenue

BioLine RX Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2017
0.00 USD
-25.24 M USD
-24.35 M USD
Jan 1, 2018
0.00 USD
-25.61 M USD
-22.96 M USD
Jan 1, 2019
0.00 USD
-28.11 M USD
-25.45 M USD
Jan 1, 2020
0.00 USD
-22.93 M USD
-30.02 M USD
Jan 1, 2021
0.00 USD
-24.78 M USD
-27.05 M USD
Jan 1, 2022
0.00 USD
-29.16 M USD
-24.95 M USD
Jan 1, 2023
4.80 M USD
-42.99 M USD
-60.61 M USD
Jan 1, 2024
28.94 M USD
-19.40 M USD
-9.22 M USD

BioLine RX Margins

BioLine RX stock margins

The BioLine RX margin analysis displays the gross margin, EBIT margin, as well as the profit margin of BioLine RX. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for BioLine RX.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2017
67.99 %
- %
- %
Jan 1, 2018
67.99 %
- %
- %
Jan 1, 2019
67.99 %
- %
- %
Jan 1, 2020
67.99 %
- %
- %
Jan 1, 2021
67.99 %
- %
- %
Jan 1, 2022
67.99 %
- %
- %
Jan 1, 2023
23.08 %
-895.65 %
-1,262.79 %
Jan 1, 2024
67.99 %
-67.03 %
-31.86 %

BioLine RX Stock analysis

What does BioLine RX do? BioLine RX Ltd is a global biopharmaceutical company specializing in the development of novel therapies for cancer and other serious diseases. The company is headquartered in Israel and has offices in the United States and Europe. BioLine RX is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioLine RX stock

Gross Profit of BioLine RX is 19.68 M USD in 2026.

Access this data via the Eulerpool API
Get Free API Key

Income Statement — BioLine RX

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — BioLine RX